JP7045333B6 - 操作されたＦｃコンストラクトに関する組成物及び方法 - Google Patents

操作されたＦｃコンストラクトに関する組成物及び方法 Download PDF

Info

Publication number
JP7045333B6
JP7045333B6 JP2018561641A JP2018561641A JP7045333B6 JP 7045333 B6 JP7045333 B6 JP 7045333B6 JP 2018561641 A JP2018561641 A JP 2018561641A JP 2018561641 A JP2018561641 A JP 2018561641A JP 7045333 B6 JP7045333 B6 JP 7045333B6
Authority
JP
Japan
Prior art keywords
domain
polypeptide
domain monomer
construct
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519528A (ja
JP2019519528A5 (https=
JP7045333B2 (ja
Inventor
カーロス ジェイ． ボスケス
ジョナサン シー． ランシング
ダニエル オルティーズ
ローラ ルチツキ
ナサニアル ジェイ． ワッシュバーン
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2019519528A publication Critical patent/JP2019519528A/ja
Publication of JP2019519528A5 publication Critical patent/JP2019519528A5/ja
Priority to JP2022044109A priority Critical patent/JP7295301B2/ja
Application granted granted Critical
Publication of JP7045333B2 publication Critical patent/JP7045333B2/ja
Publication of JP7045333B6 publication Critical patent/JP7045333B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
JP2018561641A 2016-05-23 2017-05-23 操作されたＦｃコンストラクトに関する組成物及び方法 Active JP7045333B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022044109A JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたＦｃコンストラクトに関する組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US62/340,322 2016-05-23
US201762443451P 2017-01-06 2017-01-06
US62/443,451 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022044109A Division JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたＦｃコンストラクトに関する組成物及び方法

Publications (4)

Publication Number Publication Date
JP2019519528A JP2019519528A (ja) 2019-07-11
JP2019519528A5 JP2019519528A5 (https=) 2020-07-02
JP7045333B2 JP7045333B2 (ja) 2022-03-31
JP7045333B6 true JP7045333B6 (ja) 2022-05-06

Family

ID=60412547

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018561641A Active JP7045333B6 (ja) 2016-05-23 2017-05-23 操作されたＦｃコンストラクトに関する組成物及び方法
JP2018561639A Withdrawn JP2019519527A (ja) 2016-05-23 2017-05-23 操作されたＦｃコンストラクトに関する組成物及び方法
JP2022010912A Pending JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたＦｃコンストラクトに関する組成物及び方法
JP2022044109A Active JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたＦｃコンストラクトに関する組成物及び方法
JP2024193057A Withdrawn JP2025026880A (ja) 2016-05-23 2024-11-01 操作されたＦｃコンストラクトに関する組成物及び方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018561639A Withdrawn JP2019519527A (ja) 2016-05-23 2017-05-23 操作されたＦｃコンストラクトに関する組成物及び方法
JP2022010912A Pending JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたＦｃコンストラクトに関する組成物及び方法
JP2022044109A Active JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたＦｃコンストラクトに関する組成物及び方法
JP2024193057A Withdrawn JP2025026880A (ja) 2016-05-23 2024-11-01 操作されたＦｃコンストラクトに関する組成物及び方法

Country Status (14)

Country Link
US (4) US11155640B2 (https=)
EP (2) EP3484514B1 (https=)
JP (5) JP7045333B6 (https=)
KR (3) KR102590061B1 (https=)
CN (4) CN118206639A (https=)
AU (2) AU2017272109B2 (https=)
BR (2) BR112018074056A2 (https=)
CA (2) CA3025310A1 (https=)
DK (1) DK3484514T3 (https=)
ES (1) ES2973251T3 (https=)
IL (3) IL263211B2 (https=)
PL (1) PL3484514T3 (https=)
SG (3) SG11201810465RA (https=)
WO (2) WO2017205436A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP7146771B2 (ja) * 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
US20210284717A1 (en) * 2018-07-11 2021-09-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
CN113382749A (zh) * 2018-07-11 2021-09-10 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
CA3106212A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
KR20210044783A (ko) * 2018-07-11 2021-04-23 모멘타 파머슈티컬스 인코포레이티드 CTLA-4 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
US20210238310A1 (en) * 2018-07-11 2021-08-05 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
MX2021000307A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
JP2021530989A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
BR112022010096A2 (pt) * 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
EP4255933A4 (en) * 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2257861A1 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
EP2432451A2 (en) 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
ES2623912T3 (es) * 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
IN2013MN01438A (https=) 2011-03-17 2015-06-12 Univ Ramot
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
WO2013185113A1 (en) * 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
HK1209034A1 (en) 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
BR112015008663B1 (pt) * 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104558194B (zh) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
EP3082847A1 (en) * 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
CN113248613B (zh) 2014-01-15 2024-08-23 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP7146771B2 (ja) * 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
抗体医薬品の品質評価のためのガイダンス，2012年，ｐ．１－１６，<URL: https://www.pmda.go.jp/files/000206143.pdf>

Also Published As

Publication number Publication date
CN109963869A (zh) 2019-07-02
AU2017272109B2 (en) 2024-07-25
JP2022068176A (ja) 2022-05-09
JP2019519528A (ja) 2019-07-11
AU2017272109A1 (en) 2019-01-17
IL309293A (en) 2024-02-01
ES2973251T3 (es) 2024-06-19
AU2017272111A1 (en) 2019-01-17
JP2019519527A (ja) 2019-07-11
JP7295301B2 (ja) 2023-06-20
SG11201810465RA (en) 2018-12-28
EP3464376A1 (en) 2019-04-10
WO2017205436A1 (en) 2017-11-30
CN118206639A (zh) 2024-06-18
WO2017205434A1 (en) 2017-11-30
SG11201810466PA (en) 2018-12-28
US11623964B2 (en) 2023-04-11
IL263211B2 (en) 2023-09-01
IL263213A (en) 2018-12-31
KR102462084B1 (ko) 2022-11-02
AU2017272111B2 (en) 2024-05-16
IL263211A (en) 2018-12-31
EP3464376A4 (en) 2020-03-18
KR20190021255A (ko) 2019-03-05
CA3025306A1 (en) 2017-11-30
CN109789203B (zh) 2022-08-05
KR20190026684A (ko) 2019-03-13
EP3484514B1 (en) 2023-12-06
CA3025310A1 (en) 2017-11-30
US12297291B2 (en) 2025-05-13
SG10202011624SA (en) 2021-01-28
PL3484514T3 (pl) 2024-04-29
IL263213B1 (en) 2024-01-01
EP3484514A4 (en) 2020-08-12
KR20220151025A (ko) 2022-11-11
JP2025026880A (ja) 2025-02-26
US20240067757A1 (en) 2024-02-29
US20210221917A1 (en) 2021-07-22
US11155640B2 (en) 2021-10-26
BR112018074032A2 (pt) 2019-02-26
IL263211B1 (en) 2023-05-01
BR112018074056A2 (pt) 2019-03-06
JP2022095685A (ja) 2022-06-28
KR102635635B1 (ko) 2024-02-14
NZ749279A (en) 2025-08-29
DK3484514T3 (da) 2024-01-29
CN116063540A (zh) 2023-05-05
JP7045333B2 (ja) 2022-03-31
EP3484514A1 (en) 2019-05-22
US20220049019A1 (en) 2022-02-17
KR102590061B1 (ko) 2023-10-18
IL263213B2 (en) 2024-05-01
CN109789203A (zh) 2019-05-21
NZ749292A (en) 2025-08-29
US20190284305A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
JP7045333B6 (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
EP3137506B1 (en) Compositions and methods related to engineered fc constructs
JP7611880B2 (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
CN113164590A (zh) 与靶向CCR4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
JP2021531755A (ja) 改変されたＦｃ−抗原結合ドメイン構築物に関する組成物および方法
HK40105176A (en) Compositions and methods related to engineered fc constructs
HK40005981B (en) Compositions and methods related to engineered fc constructs
HK40005981A (en) Compositions and methods related to engineered fc constructs
HK1228927B (en) Compositions and methods related to engineered fc constructs
HK1228927A1 (en) Compositions and methods related to engineered fc constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200520

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210512

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220318

R150 Certificate of patent or registration of utility model

Ref document number: 7045333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250